Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00472_DB01166_nanopub.RAd2jZ6SxmR6LsT1Ihqh4q3Vmzsl7nb_BBLWvaTHNqYmg#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00472_DB01166 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00472_DB01166 label "DDI between Fluoxetine and Cilostazol - Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB01166]" assertion.
- drugbank_resource:DB00472_DB01166 identifier "drugbank_resource:DB00472_DB01166" assertion.
- drugbank_resource:DB00472_DB01166 title "DDI between Fluoxetine and Cilostazol - Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00472 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00472_DB01166 assertion.
- drugbank:DB01166 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00472_DB01166 assertion.